C - Chemistry – Metallurgy – 12 – N
Patent
C - Chemistry, Metallurgy
12
N
C12N 15/13 (2006.01) A61K 38/17 (2006.01) A61K 38/48 (2006.01) A61K 47/48 (2006.01) C07K 16/28 (2006.01) C12N 5/12 (2006.01) C12N 15/06 (2006.01) C12N 15/62 (2006.01) C12Q 1/37 (2006.01) C12Q 1/68 (2006.01) G01N 33/53 (2006.01) G01N 33/573 (2006.01)
Patent
CA 2383462
The invention provides a method of treatment of a chronic inflammatory disease (such as rheumatoid arthritis) in a patient, the method comprising the administration to the patient of a compound that selectively inhibits Tck cells. Preferably, said compound selectively inhibits Tck cell-induced release of one or more pro-inflammatory cytokines from monocytes. Advantageously, said compound inhibits NF-.kappa.B. Conveniently, said compound activates PI3 kinase. The invention further provides a method of identifying a compound with efficacy in the treatment of a chronic inflammatory disease comprising the step of testing said compound for an ability to selectively inhibit Tck cells. Preferably, said method of identifying a compound with efficacy in the treatment of a chronic inflammatory disease comprises the step of testing said compound for an ability to selectively inhibit Tck cell-induced release of one or more pro-inflammatory cytokines from monocytes. Conveniently, the pro- inflammatory cytokine is tumour necrosis factor .alpha. (TNF.alpha.). The invention further provides compounds identifiable or identified by said methods and the use of said compounds in medicine. Additionally, the invention provides an antibody-like molecule with specificity for Tck cells, and compounds comprising said antibody-like molecule and a cytotoxic moiety.
L'invention concerne une méthode permettant de traiter une maladie inflammatoire chronique (telle que la polyarthrite rhumatoïde) chez un patient, ladite méthode consistant à administrer au patient un composé inhibant sélectivement T¿ck?. De préférence, ledit composé inhibe sélectivement la libération, induite par les lymphocytes T¿ck?, d'une ou de plusieurs cytokines pro-inflammatoires issues de monocytes. Avantageusement, ledit composé inhibe NF-.kappa.B et active opportunément la kinase PI13. L'invention concerne également une méthode permettant d'identifier un composé efficace pour le traitement d'une maladie inflammatoire chronique, ladite méthode consistant à tester ledit composé pour étudier sa capacité à inhiber sélectivement les lymphocytes T¿ck?. De préférence, ladite méthode d'identification d'un composé efficace pour le traitement d'une maladie inflammatoire chronique consiste à tester ledit composé pour étudier sa capacité à d'inhiber sélectivement la libération, induite par les lymphocytes T¿ck?, d'une ou de plusieurs cytokines pro-inflammatoires issues de monocytes. Avantageusement, cette cytokine pro-inflammatoire est le facteur de nécrose tumorale .alpha. (TNF.alpha.). L'invention concerne, en outre, des composés identifiables ou identifiés par ces méthodes, ainsi que l'utilisation desdits composés en médecine. Enfin, l'invention concerne une molécule du type anticorps spécifique des lymphocytes T¿ck?, et les composés comprenant ladite molécule du type anticorps et une fraction cytotoxique.
Brennan Fionula Mary
Feldmann Marc
Foxwell Brian Maurice John
Borden Ladner Gervais Llp
Synovis Limited
The Mathilda And Terence Kennedy Institute Of Rheumatology Trust
LandOfFree
Therapeutic methods and compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic methods and compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic methods and compounds will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1842949